产品介绍
Product Description
Biochem/physiol Actions
ABT-751 is an orally bioavailable vascular disrupting agent (VDA) with a broad spectrum of antitumor activity. It binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules.
ABT-751, a sulfonamide antimitotic agent, is under clinical trials to treat patients with various malignancies including refractory hematologic malignancies, non-small cell lung cancer (NSCLC), and colon cancer.
Orally bioavailable vascular disrupting agent (VDA) that binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules; broad spectrum of antitumor activity.
Features and Benefits
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
技术参数
Specifications
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| storage condition | desiccated |
| color | pink to purple |
| solubility | DMSO: ≥15 mg/mL |
| originator | Abbott |
| storage temp. | 2-8°C |
| SMILES string | Cl.COc1ccc(cc1)S(=O)(=O)Nc2cccnc2Nc3ccc(O)cc3 |
| InChI | 1S/C18H17N3O4S.ClH/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13;/h2-12,21-22H,1H3,(H,19,20);1H |
| InChI key | KWQWWUXRGIIBAS-UHFFFAOYSA-N |
